circPTPN12 promotes the progression and sunitinib resistance of renal cancer via hnRNPM/IL-6/STAT3 pathway

circPTPN12 promotes the progression and sunitinib resistance of renal cancer via hnRNPM/IL-6/STAT3 pathway

Abstract Renal cell carcinoma (RCC) is characterized by the difficulties in early diagnosis and the propensity to metastases. For advanced RCC, sunitinib targeted therapy is the clinically recommended first-line drug and the major challenge of sunitinib treatment is adaptive resistance. Therefore, i...

Full description

Bibliographic Details
Main Authors: Yi Shou, Changjie Yue, Qi Wang, Jingchong Liu, Jiaju Xu, Qi Miao, Di Liu, Hongmei Yang, Yuenan Liu, Xiaoping Zhang
Format: Article
Language:English
Published: Nature Publishing Group 2023-03-01
Series:Cell Death and Disease
Online Access:https://doi.org/10.1038/s41419-023-05717-z

Internet

https://doi.org/10.1038/s41419-023-05717-z

Similar Items